Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of “Buy” from Analysts

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average rating of “Buy” by the seven brokerages that are presently covering the firm, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of brokerages have recently commented on AQST. Leerink Partnrs raised shares of Aquestive Therapeutics to a “strong-buy” rating in a research report on Friday, May 10th. Raymond James began coverage on Aquestive Therapeutics in a report on Thursday, March 28th. They set an “outperform” rating and a $7.00 price objective on the stock. SVB Leerink started coverage on Aquestive Therapeutics in a research report on Friday, May 10th. They set an “outperform” rating and a $8.00 price objective on the stock. Piper Sandler started coverage on shares of Aquestive Therapeutics in a research note on Thursday, April 11th. They set an “overweight” rating and a $10.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research note on Wednesday, June 5th.

Aquestive Therapeutics Stock Up 0.4 %

AQST opened at $2.76 on Tuesday. The stock’s 50 day moving average price is $3.51 and its two-hundred day moving average price is $3.16. The firm has a market capitalization of $251.27 million, a P/E ratio of -6.57 and a beta of 2.81. Aquestive Therapeutics has a 12-month low of $1.25 and a 12-month high of $6.23.

Aquestive Therapeutics (NASDAQ:AQST) last announced its quarterly earnings data on Monday, May 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.08). The firm had revenue of $12.05 million for the quarter, compared to analyst estimates of $12.22 million. During the same quarter last year, the firm posted $0.11 EPS. As a group, analysts anticipate that Aquestive Therapeutics will post -0.45 earnings per share for the current year.

Insider Buying and Selling at Aquestive Therapeutics

In other news, insider Alexander Mark Schobel sold 50,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $6.00, for a total transaction of $300,000.00. Following the sale, the insider now owns 984,476 shares in the company, valued at $5,906,856. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 7.85% of the company’s stock.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently modified their holdings of the stock. Legato Capital Management LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth approximately $688,000. Armistice Capital LLC raised its position in shares of Aquestive Therapeutics by 314.5% during the third quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock worth $7,344,000 after acquiring an additional 3,642,000 shares during the last quarter. Acadian Asset Management LLC raised its position in shares of Aquestive Therapeutics by 238.8% during the third quarter. Acadian Asset Management LLC now owns 550,484 shares of the company’s stock worth $841,000 after acquiring an additional 388,017 shares during the last quarter. Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics during the fourth quarter valued at $60,000. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in Aquestive Therapeutics by 14.2% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 247,828 shares of the company’s stock valued at $379,000 after acquiring an additional 30,898 shares during the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.